BCM
DSGN icon

Bridgeway Capital Management’s Design Therapeutics DSGN Stock Holding History

Bridgeway Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$553K Sell
52,000
-26,500
-34% -$268K 0.01% 802
2025
Q4 		$736K Sell
78,500
-109,700
-58% -$859K 0.02% 757
2025
Q3 		$1.42M Hold
188,200
– – 0.03% 642
2025
Q2 		$634K Buy
188,200
+74,400
+65% +$278K 0.02% 731
2025
Q1 		$439K Sell
113,800
-14,600
-11% -$69.7K 0.01% 766
2024
Q4 		$792K Sell
128,400
-107,200
-46% -$621K 0.02% 716
2024
Q3 		$1.27M Hold
235,600
– – 0.03% 624
2024
Q2 		$789K Buy
235,600
+89,700
+61% +$349K 0.02% 751
2024
Q1 		$588K Hold
145,900
– – 0.01% 878
2023
Q4 		$387K Buy
145,900
+65,400
+81% +$150K 0.01% 1004
2023
Q3 		$190K Buy
+80,500
New +$375K ﹤0.01% 1112

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Bridgeway Capital Management's DSGN Position: Q1 2026 in Review

Bridgeway Capital Management reduced its Design Therapeutics (DSGN) stake by 34% in Q1 2026, selling an estimated $268K and leaving 52,000 shares worth $553K. The position accounts for 0.01% of the portfolio, ranked #802.

Bridgeway Capital Management first reported a position in DSGN in Q3 2023 and has held it in 11 quarters since. The position peaked at $1.42M in Q3 2025. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Bridgeway Capital Management held 52,000 shares of Design Therapeutics worth $553K as of Q1 2026.
  • Bridgeway Capital Management sold 26,500 Design Therapeutics shares in Q1 2026, an estimated $268K.
  • Design Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #802 holding.
  • Bridgeway Capital Management first reported a position in Design Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Bridgeway Capital Management's Design Therapeutics position peaked at $1.42M in Q3 2025.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.